9800 Medical Center Ste D
7 articles with ABL, Inc.
TRIGR Therapeutics Expands Bispecific Immuno-Oncology Pipeline with Exclusive Global License of Clinical Stage, Dual Angiogenesis Inhibitor from ABL Bio
TRIGR to lead clinical development of TR009, a dual VEGF/DLL4 BsAb showing early single agent activity in heavily pretreated, Avastin® and immunotherapy refractory patients with solid tumors
ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France
ABL, Inc. is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe SAS (ABL Europe), of a 6,500 m2 GMP manufacturing site located in Lyon, France.
ABL, Inc. (ABL), a leading global contract research and manufacturing service provider to the biopharmaceutical industry, announces the appointment of Jarlath Keating as the new President and Chief Executive Officer of ABL, succeeding Dr. Thomas VanCott.
ABL Awarded Long-Running National Cancer Institute Contract to Continue Groundbreaking Retroviral Research
ABL, Inc (ABL), a global contract research and manufacturing service provider, is pleased to announce it was awarded the "Support for Research on Retroviral Pathogenesis, Treatment and Prevention" contract by the National Cancer Institute (NCI) to conduct studies that advance the development of effective AIDS vaccines and other preventive therapeutic modalities
ABL, Inc. announces the hire of Jarlath Keating as Chief Commercial Officer (CCO).
ABL, Inc. announces the hire of Marykay Marchigiani as Chief Financial Officer (CFO).
Under the current agreement, ABL is currently manufacturing Pexa-Vec for SillaJen's multinational, randomized Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer.